Published in Nat Rev Urol on January 01, 2010
Detecting Bladder Cancer Using the UroMark Test. (DETECT I) | NCT02676180
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer. PLoS One (2015) 1.39
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol (2011) 1.20
Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol Cell Proteomics (2011) 1.14
Long interspersed nuclear element-1 hypomethylation and oxidative stress: correlation and bladder cancer diagnostic potential. PLoS One (2012) 0.94
Contemporary management of low-risk bladder cancer. Nat Rev Urol (2011) 0.93
Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol (2012) 0.88
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med (2012) 0.85
Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol (2016) 0.82
Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder. World J Urol (2013) 0.82
Urine telomerase for diagnosis and surveillance of bladder cancer. Adv Urol (2012) 0.81
Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway. J Proteome Res (2016) 0.81
Urinary tract cancers: An overview for general practice. J Family Med Prim Care (2017) 0.75
Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. Sci Rep (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics (2003) 4.99
Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A (2007) 3.48
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA (2006) 3.41
Comparison of screening methods in the detection of bladder cancer. J Urol (1999) 2.67
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol (2006) 2.14
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer (2006) 1.92
A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol (2000) 1.81
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology (2003) 1.79
Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol (2009) 1.79
A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol (2004) 1.71
Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol (2009) 1.66
Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int (2008) 1.60
Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int (2008) 1.58
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer (1989) 1.53
Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology (1995) 1.48
Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol (2002) 1.48
Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician (2001) 1.42
Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol (2001) 1.41
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol (2000) 1.22
Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol (1993) 1.22
Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol (2006) 1.18
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther (2007) 1.13
Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol (2003) 1.12
Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol (2006) 1.12
Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol (2006) 1.11
Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn (2003) 1.07
Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol (2004) 1.05
Hematuria home screening: repeat testing results. J Urol (1995) 1.04
uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer (2006) 1.04
Long-term outcome of home dipstick testing for hematuria. World J Urol (2007) 1.03
Urinary tract cancer screening through analysis of urinary red blood cell volume distribution. Int J Urol (2000) 1.03
Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol (2001) 1.02
Molecular staging of bladder cancer. BJU Int (2005) 1.02
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol (2002) 1.01
Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol (1999) 1.00
A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol (1992) 0.99
Complement factor H as a marker for detection of bladder cancer. Clin Chem (2005) 0.98
The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology (2006) 0.98
Urinary bladder tumor markers. Urol Oncol (2006) 0.96
Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer (2006) 0.96
A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol (1997) 0.94
uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology (2006) 0.94
ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol (2005) 0.93
Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol (2002) 0.92
Bladder cancer: natural history, tumor markers, and early detection strategies. Semin Surg Oncol (1997) 0.92
Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer (1998) 0.91
Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology (2001) 0.89
Home screening for hematuria: results of a multiclinic study. J Urol (1992) 0.89
Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int (2007) 0.88
Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst (2005) 0.88
'Superficial' bladder cancer - time to uncouple pT1 tumours from pTa tumours. BJU Int (2002) 0.87
Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology (2000) 0.87
Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India (2006) 0.84
The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res (2005) 0.84
Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res (2003) 0.82
Economics of notification and medical screening for high-risk workers. J Occup Med (1986) 0.82
Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol (2003) 0.82
The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol (2008) 0.82
Current state of screening for bladder cancer. Expert Rev Anticancer Ther (2007) 0.81
Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol (2001) 0.80
Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol (2006) 0.79
Searching for novel therapeutics and targets: insights from clinical trials. Urol Oncol (2007) 0.78
Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology (1996) 0.77
Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Ann Clin Lab Sci (2006) 0.77
Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor. Arch Ital Urol Androl (2006) 0.76
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A (2007) 3.48
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem (2002) 2.16
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol (2006) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices (2011) 2.10
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nanotubes. J Am Chem Soc (2005) 1.97
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol (2009) 1.79
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol (2004) 1.77
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol (2007) 1.74
Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res (2006) 1.73
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol (2011) 1.59
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer (2006) 1.44
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer (2008) 1.39
Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol (2009) 1.32
Circulating tumor cells: from bench to bedside. Annu Rev Med (2012) 1.29
Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. Am J Clin Pathol (2008) 1.21
High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. J Mol Diagn (2009) 1.21
Disseminated and circulating tumor cells: Role in effective cancer management. Crit Rev Oncol Hematol (2010) 1.20
p53 and retinoblastoma pathways in bladder cancer. World J Urol (2007) 1.16
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol (2010) 1.15
Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes. ACS Nano (2009) 1.14
Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther (2007) 1.13
Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol (2003) 1.11
Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int (2011) 1.10
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Molecular staging of bladder cancer. BJU Int (2005) 1.02
A calibration method for nanowire biosensors to suppress device-to-device variation. ACS Nano (2009) 0.97
Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev (2009) 0.97
Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer (2006) 0.96
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int (2009) 0.94
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol (2004) 0.94
LM-PCR permits highly representative whole genome amplification of DNA isolated from small number of cells and paraffin-embedded tumor tissue sections. Diagn Mol Pathol (2004) 0.94
Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn (2012) 0.92
Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int (2006) 0.92
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol (2015) 0.91
Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer (2004) 0.89
Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol (2012) 0.88
Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther (2010) 0.88
Genetic and epigenetic analysis of putative breast cancer stem cell models. BMC Cancer (2013) 0.87
Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res (2005) 0.85
Rapid, label-free, electrical whole blood bioassay based on nanobiosensor systems. ACS Nano (2011) 0.85
Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India (2006) 0.84
A modified reduced-temperature antigen retrieval protocol effective for use with a polyclonal antibody to cyclooxygenase-2 (PG 27). Appl Immunohistochem Mol Morphol (2002) 0.83
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol (2012) 0.81
The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol (2004) 0.80
Role of genetic and expression profiling in pharmacogenomics: the changing face of patient management. Curr Issues Mol Biol (2002) 0.79
Micrometastasis: detection methods and clinical importance. Cancer Biomark (2010) 0.79
Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. J Clin Oncol (2005) 0.79
Searching for novel therapeutics and targets: insights from clinical trials. Urol Oncol (2007) 0.78
Molecular targets and targeted therapies in bladder cancer management. World J Urol (2008) 0.78
The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. Urol Oncol (2007) 0.77
Importance of controlling nanotube density for highly sensitive and reliable biosensors functional in physiological conditions. ACS Nano (2010) 0.77
Prevention of prostate cancer with finasteride. N Engl J Med (2003) 0.77
Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation. Clin Chem (2011) 0.77
Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales? Expert Rev Anticancer Ther (2011) 0.77
Classical pathology versus molecular pathology in renal cell carcinoma. Curr Urol Rep (2007) 0.77
Pathological possibilities and pitfalls in detecting aggressive bladder cancer. Curr Opin Urol (2012) 0.76
Occult metastases: real harm or false alarm? J Thorac Cardiovasc Surg (2003) 0.75
Re: Joseph Chin. In Search of the Perfect Crystal Ball for Ta Urothelial Cancer. Eur Urol. doi:10.1016/j.eururo.2009.09.014. Eur Urol (2009) 0.75
Editorial comment. Urology (2010) 0.75
A surface acoustic wave biosensor for interrogation of single tumour cells in microcavities. Lab Chip (2015) 0.75
Highly scalable, uniform, and sensitive biosensors based on top-down indium oxide nanoribbons and electronic enzyme-linked immunosorbent assay. Nano Lett (2015) 0.75
Pathologic quiz case: a 41-year-old woman with bilateral nodular breasts. Arch Pathol Lab Med (2002) 0.75